Clinical treatment of 48 cases with bone metastasis / 中国基层医药

Objective To explore the outcomes of radiotherapy and zoledronic acid in patients with bone metastasis.Methods 48 cancer patients with bone metastasis,were divided into two group,control group received radiotherapy only,therapy group received radiotherapy and zoledronic acid.Remission of ostalgia was evaluated after 3-6 months.Results The total effective of remission of ostalgia had no significant differences between two group(83.3 ％ vs 79.2％,P ＜ 0.05).But rate of complete remission therapy group was higher than that of control group(50.0％ vs 33.3％,P ＜ 0.05).The adverse reaction aer resemble between the two group.Conclusion The outcomes of radiotherapy and zoledronic acid in patients with bone metastasis is effectiveness for cases with bone metastasis,is worth spreading.

Recurrent ovarian cancer metastatic to the bone: Case report / 대한산부인과학회지

In patients with gynecologic malignancies, bone metastases are unusual and generally occur in a more advanced stage of the disease with extended local invasion of the primary site and/or parenchymal metastasis. In ovarian cancer, the main route of spread is intraperitoneal implantation and loco-regional invasion, whereas extraperitoneal spread usually implies advanced disease. Bone metastasis from ovarian cancer is rare and occurs in approximately 1% of primary or recurrent disease. The prognosis of cases with bone metastasis is poor. We report a patient with metastases to the sternum and a rib after prolonged treatment and a patient with recurrent ovarian cancer metastatic to the sacrum 8 months after primary treatment.

Bifosfonatos y osteonecrosis de los maxilares: consideraciones sobre su tratamiento / Biphosphonate and jaws osteonecrosis: considerations about of treatment

Los bifosfonatos son potentes inhibidores de los osteoclastos, son drogas usadas principalmente para el tratamiento de mieloma múltiple y en metástasis óseas de tumores sólidos como el cáncer de mama. En el año 2003 fue relatado el primer caso de osteonecrosis de los maxilares (ONM) asociado al uso de bifosfonatos, sin embargo aun no se ha establecido una relación causa efecto de estas drogas sobre la ONM. La incidencia en tiempos anteriores en relación al uso de bifosfonatos era muy baja, siendo que hoy día alcanza 10 por ciento o más en las patologías mencionadas tratadas con estas drogas. Este artículo tiene por objetivo alertar sobre una posible complicación en pacientes que hacen uso de bifosfonatos, a través de la revisión de la literatura y la presentación de un caso clínico.

Bisphosphonates are strong osteoclastic inhibitor activities, being these drugs usually for treatment of multiple myeloma and bone metastases of solid tumors like breast cancer. The osteonecrosis of the maxillary bones was first described in 2003. The relation of these medicines and maxillary bone osteonecrosis still uncertain. The incidence of this bone necrosis was very low before biphosphonates using. Nowadays this complication reach at least 10 percent of patients in these therapy using. The present work mean to alert for possible complication in biphosphonates using patients, thru a literature review and a clinical case presentation.

Value of Bone Scan in Addition to F-18 FDG PET/CT and Characteristics of Discordant Lesions between F-18 FDG PET/CT and Bone Scan in the Spinal Bony Metastasis / 핵의학분자영상

PURPOSE: Our purpose was to evaluate spinal bony metastasis which could be missed on an F-18 FDG PET/CT (FDG PET/CT) alone, and to characterize discordant metastatic lesions between FDG PET/CT and bone scan. MATERIAL AND METHODS: FDG PET/CT and bone scans of 43 patients with spinal bony metastasis were analyzed retrospectively. A McNemar test was performed comparing the FDG PET/CT alone to the FDG PET/CT plus bone scan in the spinal bony metastases. A one-way chi-square test was performed to characterize the metastases that were missed on the FDG PET/CT alone. To evaluate discordant lesions between FDG PET/CT and bone scan, we performed logistic regression analyses. The independent variables were sites (cervical, thoracic, and lumbar), size (large and small), and maximum SUVs, and the dependant variable was bone scan uptake (positive and negative MDP uptake). RESULTS: A significant difference was found between the FDG PET/CT alone and the FDG PET/CT combined with the bone scan (p<0.01). Using the FDG PET/CT only, diffuse osteoblastic metastasis was missed with a significantly higher frequency (p=0.04). In the univariate analysis, cervical vertebra and small size were related to negative MDP uptake, and thoracic vertebra and large size were related to positive MDP uptake. However, in the multivariate analysis, only the large size was related to positive MDP uptake. CONCLUSION: A bone scan in addition to the FDG PET/CT increased the ability to evaluate spinal bony metastases, especially for diffuse osteoblastic metastasis. Large metastasis was related to positive bone scan uptake in spinal bony metastasis.

Analysis on the Utilization of Drug for Bony Metastasis Cancer in Our Hospital from 2006 to 2009 / 中国药房

OBJECTIVE:To investigate the status quo and tendency of the utilization of drug for bony metastasis cancer in our hospital. METHODS:The utilization of drug for bony metastasis cancer in our hospital from 2006 to 2009 was analyzed statistically. RESULTS:The total amount of the drug for bony metastasis cancer had been increasing. Pamidronate took up the first place of the consumption sum list and accounted for 80% of total consumption sum. Top one drug in the list of DDDs was domestical pamidronate. Utilization rate of disodium clodronate increased form 0.67% in 2006 to 31.68% in 2009. The order of DDC had not changed during 2006～2009. CONCLUSION:In recent year the drug for bony metastasis cancer has been rational and has become curative effect-oriented rather than price-oriented.

Relation of alpha-1-antichymotrypsin and p53 Protein Expression to Bony Metastasis in Advanced Prostate Cancer / 대한비뇨기과학회지

PURPOSE: The purpose of this study was to investigate whether the expressions of alpha-1 -antichymotrypsin(ACT) and/or p53 protein in advanced prostate cancer were related with bony metastases. MATERIALS AND METHODS: The immunohistochemical study with ACT and p53 included 7 archival transurethral resection and 14 prostate biopsy specimens from patients with prostate cancer who showed high serum PSA level(>10ng/ml) and periprostatic or lymph node involvement on imaging study. Whole body bone scan was perfomed to detect bony metastatis in all patients. RESULTS: Four out of 5 cases showing strong expression patterns with ACT protein showed abnormal hot uptakes on whole body bone scan. ACT proteins were weakly expressed in seven out of eight cases without bony metastases. p53 protein was expressed in 13 cases, but there was no statistically significant relation between the expression of p53 protein and bony metastasis. Either, there was no significant relation between ACT and p53 protein expression patterns. CONCLUSIONS: Our results suggested that the strong expression of ACT protein combined with high serum PSA level(>10ng/ml) and whole body bone scan could be the useful method for confirming bony metastasis although not adequate for screening test. The expression of p53 protein appears to be associated with progression of prostate cancer, but there was no statistically significant relation with bony metastasis.